Utilizing The GPEx Suite Of Technologies For Cell Line Development

Source: Catalent

Biopharmaceutical products in development continue to increase in complexity, which poses a challenge for pharmaceutical companies looking to improve speed and efficiency of biologic development. Cell line development is a critical step in the development process, impacting protein quality, manufacturing scalability/efficiency and timelines. The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines. The GPEx platform is particularly beneficial for complex proteins, such as multi-specific antibodies, unique protein fusions, bioconjugates (including ADCs), proteins requiring cleavage and proteins requiring other post-translational modification not typically performed by CHO cells.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader